Compare Chemfab Alka. with Similar Stocks
Dashboard
Poor long term growth as Operating profit has grown by an annual rate -6.47% of over the last 5 years
The company has declared negative results for the last 2 consecutive quarters
With ROCE of 1.8, it has a Expensive valuation with a 1.4 Enterprise value to Capital Employed
Despite the size of the company, domestic mutual funds hold only 0.25% of the company
Underperformed the market in the last 1 year
Stock DNA
Commodity Chemicals
INR 543 Cr (Micro Cap)
NA (Loss Making)
39
0.29%
0.29
0.82%
1.56
Total Returns (Price + Dividend) 
Latest dividend: 1.2 per share ex-dividend date: Sep-04-2025
Risk Adjusted Returns v/s 
Returns Beta
News
Are Chemfab Alkalis Ltd latest results good or bad?
Chemfab Alkalis Ltd's latest financial results for Q3 FY26 indicate a company facing significant operational challenges. The net sales for the quarter were reported at ₹68.14 crores, reflecting a decline of 18.51% year-on-year and a sequential decrease of 11.00%. This marks the third consecutive quarter of falling sales, with cumulative revenue down 25.56% over the last two quarters. The company's net profit was a loss of ₹4.45 crores, a stark contrast to a profit of ₹3.64 crores in the same quarter last year, representing a substantial year-on-year decline. The operating margin also contracted sharply to 2.85%, down from 14.24% a year ago, indicating severe pricing pressures or cost inflation that the company has struggled to manage. Additionally, the operating profit before depreciation, interest, tax, and other income (PBDIT excluding other income) fell to ₹1.94 crores, the lowest in seven quarters, hi...
Read full news article
Chemfab Alkalis Ltd Falls to 52-Week Low Amidst Continued Downtrend
Chemfab Alkalis Ltd’s shares declined sharply to a fresh 52-week low of Rs.374.95 on 29 Jan 2026, marking a significant drop amid a sustained downtrend that has seen the stock underperform its sector and broader market indices over the past year.
Read full news article
Chemfab Alkalis Q3 FY26: Mounting Losses and Margin Collapse Signal Deepening Operational Crisis
Chemfab Alkalis Ltd., a micro-cap commodity chemicals manufacturer, reported a deeply concerning Q3 FY26 performance, with net losses widening to ₹4.45 crores—a staggering 336.70% deterioration compared to the ₹1.88 crores profit recorded in Q3 FY25. The Chennai-based caustic soda and chlorine producer has now posted consecutive quarterly losses, with operating margins collapsing to a mere 2.85%, down from 14.24% in the year-ago quarter. The stock plunged 7.66% following the results, trading at ₹379.35 and hovering perilously close to its 52-week low of ₹374.95.
Read full news article Announcements 
Board Meeting Intimation for Board Meeting Intimation For Approving Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025 Among Other Items.
22-Jan-2026 | Source : BSEChemfab Alkalis Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2026 inter alia to consider and approve Board Meeting Intimation - The meeting of the Board of Directors of the Company is scheduled on 28/01/2026 inter alia to consider and approve Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2025 among other items.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
12-Jan-2026 | Source : BSESubmission of certificate received from RTA for compliance under Reg. 74(5) of SEBI (DP) Regulation 2018.
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Company Update
06-Jan-2026 | Source : BSESubmission of intimation that the Company has successfully commissioned the latest generation INEOS Electrolyser replacing existing 30year old 2nd generation UHDE Electrolyser and associated equipment to improve overall efficiency and optimize costs.
Corporate Actions 
No Upcoming Board Meetings
Chemfab Alkalis Ltd has declared 12% dividend, ex-date: 04 Sep 25
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 2 Schemes (0.07%)
Held by 2 FIIs (0.08%)
Dr Rao Holdings Pte Ltd (47.04%)
V. M. Srinivasan (1.8%)
21.56%
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
QoQ Growth in quarter ended Dec 2025 is -11.00% vs -16.36% in Sep 2025
QoQ Growth in quarter ended Dec 2025 is -121.39% vs -178.82% in Sep 2025
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 6.10% vs -0.14% in Sep 2024
Growth in half year ended Sep 2025 is 50.00% vs -97.39% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is -2.40% vs -1.20% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -274.55% vs -89.29% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 2.16% vs -1.23% in Mar 2024
YoY Growth in year ended Mar 2025 is -126.37% vs -59.24% in Mar 2024






